Hexameric Mn(II) dendrimer as MRI contrast agent

Area of Science:

• Biomedical Imaging
• Nanotechnology
• Materials Science

Background:

• Gadolinium (Gd(III))-based contrast agents are widely used in MRI.
• Concerns exist regarding the long-term retention and potential toxicity of Gd(III) in patients, particularly those with renal impairment.

Purpose of the Study:

• To develop and evaluate a novel manganese (Mn(II))-chelating dendrimer as a potential MRI contrast agent.
• To compare the performance of the Mn(II) dendrimer with a clinically used Gd(III) agent.

Main Methods:

• Synthesis of a Mn(II) dendrimer using a cyclotriphosphazene core and tyrosine-derived moieties.
• Characterization using variable temperature (17)O NMR spectroscopy.
• Relaxivity measurements across a range of magnetic field strengths.
• In vivo imaging and pharmacokinetic studies in mice, comparing with Gd(DTPA).

Main Results:

• The Mn(II) dendrimer demonstrated fast water exchange and high relaxivity per molecule, significantly higher than Gd(III) agents.
• In vivo studies showed twofold greater blood signal enhancement with the Mn(II) dendrimer compared to Gd(DTPA).
• The dendrimer exhibited rapid blood clearance via renal and hepatobiliary routes.

Conclusions:

• The Mn(II) dendrimer is a promising MRI contrast agent with superior relaxivity and favorable pharmacokinetic properties.
• It represents a potential alternative to Gd(III)-based agents, especially for patients with chronic kidney disease where Gd(III) use may be contraindicated.